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Abstract of poster presented orally in the moderated poster session at the International 
Open NanoScience Congress, 26.2.2019, Salzburg (www.uni-salzburg.at/ONSC) 
Over 100 years ago, Paul Ehrlich first proposed the side-chain theory to explain how living cells 
mount an immune response in reaction to an infection. His theory stated that upon the 
encounter of a threat, cells express side-chains to bind dangerous toxins. These side-chains, 
which he later named receptors, can break off the cell and circulate throughout the body (i.e. 
antibodies). Specific antibodies link to particular antigens in the same way that Emil Fischer 
proposed enzymes bind to their receptors, “as lock and key”. Ehrlich described these so-called 
“keys” or antibodies as “magic bullets”, which target toxins without harming the body. In recent 
years, research has focused on using antibodies not only for detection of infection, but also as 
aids for drug targeting. Thereby, antibodies are bound to the surface of carriers (e.g. 
nanoparticles) and facilitate a directed transport to a specific organ or site in the body. Aptamer-
, peptide- or folic acid-doped carriers furthermore have been shown to specifically target cancer 
cells. By using hydrophilic structures as carriers (e.g. polyethylene glycol), negative side effects 
resulting from the accumulation of innate proteins can be prevented. Currently, there are drug 
carriers in the pre-clinical development phase for the treatment of bowel cancer. Thereby, nano 
polymer capsules coated with a specific antibody are used to target a glycoprotein expressed on 
bowel cancer cells. The polymers have a size of approximately 500 nm and are produced with a 
so-called “layer-by-layer” procedure. Once the carrier has reached its target site, the drug needs 
to be released in a controlled manner. This can be facilitated, for example, by applying a magnetic 
field in the case of iron oxide particles. Once these particles are taken up by the cells, magnetic 
radiation can be used to excite the particles, resulting in the rupture of the cell and subsequent 
cell death. 
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Hintergrund 
Vor ca. 100 Jahren hatte Paul Ehrlich bereits die 
Vision von „Zauberkugeln“ -  Arzneistoffen, die 
spezifisch auf Krebszellen wirken und gesunde 
Zellen unbeschadet lassen  Antikörper binden 
nach dem 
„Schlüssel-Schloss“-Prinzip 
Aktives Drug Targeting 
Welche „Schlüssel“ gibt es? 
Nanoträgerstoffe transportieren Therapeutika 
gezielt an ihr Zielorgan, z.B. mit Hilfe eines 
Antikörpers, der an die Oberfläche der 
Nanoträgerstoffe gebunden ist. 
 
Alternativ binden Aptamer-, Peptid- oder 
Folsäure-dotierte Trägerstoffe spezifisch an 
Krebszellen. 
 
Die Oberfläche ist mit hydrophilen Strukturen 
versehen, um Nebenwirkungen zu minimieren 
und die Anlagerung von körpereigenen 
Proteinen zu verhindern (Polyethylenglykol). 
Johanna Erian und Lois-Marie Vince, HLW St. Veit/Glan 
Lysosomen 
Nan-O-Style ist ein Sparkling Science Projekt mit Unterstützung durch das 







Freisetzung des Therapeutikums aus Lysosomen mittels Magnetfeld 
In präklinischer Entwicklung 
Darmkrebszellen reichern Glykoprotein A33 auf 
ihrer Oberfläche an  anti-A33-dotierte Nano-
Polymerkapseln (~500 nm), mittels „Schicht-für-
Schicht“-Verfahren hergestellt, binden spezifisch  Aptamere sind kurze, einzelsträngige DNA- oder 
RNA-Sequenzen, die Strukturen annehmen und 
Liganden spezifisch binden können 
Antikörper Peptid 
Aptamer Folsäure 
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